Prolonged succinylcholine action during electroconvulsive therapy (ECT) after cytarabine, vincristine, and rituximab chemotherapy. uri icon

Overview

abstract

  • Succinylcholine is a depolarizing neuromuscular blocker frequently used during electroconvulsive therapy. In most patients, the duration of paralysis is brief, allowing for spontaneous respiration shortly after the therapy. We report a case of delayed return of neuromuscular function after succinylcholine administered during electroconvulsive therapy in a 72-year-old man receiving cytarabine, vincristine, and rituximab chemotherapy for chronic lymphocytic leukemia. We hypothesize that an interaction between succinylcholine and one of the chemotherapeutic agents caused the prolongation of paralysis and believe that this is the first reported case of prolonged duration of succinylcholine following this regimen of chemotherapy. Despite this unexpected prolonged neuromuscular blockade, the patient could be treated uneventfully, with attention paid to his respiratory support and with subsequent succinylcholine dose titration to effect.

publication date

  • March 1, 2011

Research

keywords

  • Antibodies, Monoclonal, Murine-Derived
  • Cytarabine
  • Drug Therapy, Combination
  • Electroconvulsive Therapy
  • Neuromuscular Depolarizing Agents
  • Succinylcholine
  • Vincristine

Identity

Scopus Document Identifier

  • 79952189806

Digital Object Identifier (DOI)

  • 10.1097/YCT.0b013e3181ff2e47

PubMed ID

  • 21206375

Additional Document Info

volume

  • 27

issue

  • 1